Our study on the transition from chronic pancreatitis to pancreatic cancer was accepted for poster presentation with travel grant support, focusing on TG2 fibrosis, senescence and neuroimmune pain.
Our pancreatic cancer research direction has been accepted for presentation at the Pancreatic Cancer Conference 2026 in London, with travel grant support.
The study focuses on the biological transition from chronic pancreatitis to pancreatic cancer, with emphasis on neuroimmune pain, TG2-associated fibrosis, senescence-driven microenvironmental persistence and stromal resistance.
This work is part of a broader doctoral and translational oncology programme designed to understand how fibrosis, senescence, extracellular matrix remodelling and tumour–stroma interactions contribute to pancreatic cancer progression and therapy resistance.